Evoke Pharma restates FY 2023 and interim 2023 financials over note classification error

Evoke Pharma Inc

Audit Committee determined prior financials for FY2023, Q2 and Q3 2023 are non-reliable due to classification error.
Note payable to Eversana misclassified as long-term instead of current; net profit trigger allowed termination.
Error had no impact on total assets, liabilities, equity, or operations; only balance sheet classification.
Material weakness in internal control over financial reporting identified; remediation plan to be filed.
Restated financial statements for affected periods expected on Form 10-K/A as soon as practicable.

item 4.02

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Evoke Pharma Inc reported that prior financial statements should not be relied upon.

Action: non reliance

Exact text from the filing

the Company’s previously issued financial statements as of and for the year ended December 31, 2023, and quarterly reports as of and for the periods ended June 30, 2023 and September 30, 2023 (the “Affected Periods”) should no longer be relied upon due to an error identified in the Affected Periods in the classification of a note payable

View on SEC.gov

47 auditor changes filed in the last 30 days. Browse all auditor changes →

Source: SEC EDGAR

accession 0000950170-24-059477

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.